Haemonetics Announces Q1 FY26 Earnings Release and Conference Call
ByAinvest
Thursday, Jul 10, 2025 2:10 am ET1min read
GS--
As of July 2, 2025, Haemonetics Corp's stock price stands at $78.64, with a day's range of $77.60 to $79.93 and a 52-week range of $55.30 to $94.99. The company has a market capitalization of $3.8 billion, with 48.04 million shares outstanding. Analysts have a bullish sentiment, with eight analysts revising their earnings downwards for the upcoming period. The company has also been aggressively buying back shares, which could positively impact its earnings per share (EPS).
Haemonetics Corp's revenue for the past year was $1.36 billion, with net income of $167.679 million and EPS of $3.33. The company's gross profit margin is 57.2%, and its return on assets is 7.2%. The company's management has been actively participating in industry conferences, such as the Goldman Sachs 46th Annual Global Healthcare Conference, where they discussed strategic growth and challenges.
Investors and financial professionals should closely monitor the Q1 FY26 financial results and the accompanying conference call to assess the company's financial health and operational performance. The medical technology sector is highly competitive, and Haemonetics Corp's ability to maintain its market position and adapt to industry changes will be critical for its long-term success.
References:
[1] https://www.investing.com/equities/haemonetics-corp
HAE--
Haemonetics Corp will release its Q1 FY26 financial results on August 7, 2025. The company will also host a conference call at 8:00 am ET to discuss the results with investors and analysts. As a financial analyst, the announcement provides an opportunity to assess the company's financial health and operational performance. The medical technology sector is highly competitive, and timely financial disclosures can influence investor confidence and market perception.
Haemonetics Corp (NYSE: HAE) is set to release its Q1 FY26 financial results on August 7, 2025, along with a conference call at 8:00 am ET to discuss the performance with investors and analysts. The medical technology sector is highly competitive, and timely financial disclosures can significantly influence investor confidence and market perception.As of July 2, 2025, Haemonetics Corp's stock price stands at $78.64, with a day's range of $77.60 to $79.93 and a 52-week range of $55.30 to $94.99. The company has a market capitalization of $3.8 billion, with 48.04 million shares outstanding. Analysts have a bullish sentiment, with eight analysts revising their earnings downwards for the upcoming period. The company has also been aggressively buying back shares, which could positively impact its earnings per share (EPS).
Haemonetics Corp's revenue for the past year was $1.36 billion, with net income of $167.679 million and EPS of $3.33. The company's gross profit margin is 57.2%, and its return on assets is 7.2%. The company's management has been actively participating in industry conferences, such as the Goldman Sachs 46th Annual Global Healthcare Conference, where they discussed strategic growth and challenges.
Investors and financial professionals should closely monitor the Q1 FY26 financial results and the accompanying conference call to assess the company's financial health and operational performance. The medical technology sector is highly competitive, and Haemonetics Corp's ability to maintain its market position and adapt to industry changes will be critical for its long-term success.
References:
[1] https://www.investing.com/equities/haemonetics-corp
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet